Research Medical autologous fibrinogen sealant to enter clinicals for hemostasis.
This article was originally published in The Gray Sheet
Executive Summary
RESEARCH MEDICAL'S AUTOLOGOUS FIBRINOGEN DELIVERY KIT U.S. CLINICALS, which are slated to begin this month at the University of New York at Stony Brook, will evaluate use of the AFD kit as a means of achieving topical hemostasis for the treatment of excessive bleeding from the donor skin site of burn patients. The company received an FDA investigational device exemption in April for the feasibility study, which will involve 12 to 15 subjects.